Investing.com - Aslan Pharma ADR reported on Friday first quarter earnings that missed analysts' forecasts and revenue that was inline with expectations.
Aslan Pharma ADR announced earnings per share of $-0.16 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $-0.14 on revenue of $0.00.
Aslan Pharma ADR shares are down 21.7% from the beginning of the year and are trading at $0.877 , down-from-52-week-high.They are under-performing the Nasdaq which is down 10.23% from the start of the year.
Aslan Pharma ADR shares lost 4.58% in intra-day trade after the report.
Aslan Pharma ADR follows other major Healthcare sector earnings this month
Aslan Pharma ADR's report follows an earnings missed by Merck ADR on Thursday, March 3, 2022, who reported EPS of $0.4558 on revenue of $5.77B, compared to forecasts EPS of $0.4818 on revenue of $5.88B.
Moderna had beat expectations on Thursday, February 24, 2022 with fourth quarter EPS of $11.29 on revenue of $7.21B, compared to forecast for EPS of $9.96 on revenue of $6.8B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar